A dozen years of clinical trials performing advanced cell therapy with perinatal cells

In this excerpt from a recent Future Science OA publication, Frances Verter, Pedro Silva Couto and Alexey Bersenev discuss trends in perinatal cell therapy for the years 2005–2017.

Go to the profile of Future Science OA
Oct 30, 2018
0
0

Since 2010, the number of clinical trials per year that rely on the action of perinatal cells unique to cord blood has been between 10 and 20 trials per year, averaging 14 trials per year. Note that this does not include standard hematopoietic stem cell transplantation trials because they do not meet our criteria of only archiving advanced cell therapy. Meanwhile, the number of clinical trials that rely on cells from other perinatal sources doubled over the 5 years from 2013 to 2017, from 28 to 56. The majority of this growth, averaging 84% of the other perinatal trials since 2010, is from clinical trials that rely solely on mesenchymal stem/stromal cells (MSCs) from any perinatal sources, including cord blood, cord tissue and the placenta.

Read the full Open Access article>>

Go to the profile of Future Science OA

Future Science OA

Open Access Journal, Future Science Group

Future Science OA is an online, open access (CC-BY), peer-reviewed title from Future Science Group. The journal’s broad coverage includes all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. All original research articles that have been conducted with scientific rigor and research integrity will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.

No comments yet.